Riskpilot← Back to searchSign inGet full accessInnosurge Trauma AB
ABActiveOrg 5591565576Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20180 employees
Revenue 2024
SEK 5,1M
-19% vs 2023
EBITDA margin
32.4%
+17% vs 2023
Equity ratio
81.1%
Financial strength
Net profit 2024
SEK 1,3M
+17% vs 2023
| Revenue | SEK 5,1M | -19% |
| EBITDA | SEK 1,6M | +17% |
| Net profit | SEK 1,3M | +17% |
| Total assets | SEK 5,4M | +29% |
| Equity | SEK 4,4M | +43% |
| Employees | 0 | — |
Legal name
Innosurge Trauma AB
Org number
5591565576
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
23 april 2018
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna suppleanten
Company purpose
Bolaget ska bedriva partihandel med hälsoprodukter.
Address
Email
bp@innosurge.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 3 232 | 3 732 | 4 510 | 6 236 | 5 052 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 465 | 975 | 611 | 1 397 | 1 635 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 465 | 975 | 611 | 1 397 | 1 635 |
| Net financials | −35 | −12 | −24 | 8 | 5 |
| Profit before tax | 431 | 963 | 587 | 1 406 | 1 640 |
| Tax | −92 | −200 | −123 | −292 | −340 |
| Net profit | 339 | 763 | 464 | 1 114 | 1 300 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 1 123 | 2 275 | 2 656 | 4 159 | 5 375 |
| Equity | 716 | 1 479 | 1 943 | 3 056 | 4 357 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 407 | 796 | 714 | 1 103 | 1 018 |
| Total debt | 407 | 796 | 714 | 1 103 | 1 018 |
EBITDA margin
32.4%
This company
15.8%
Market median
+105% vs market
20202024
Equity ratio
81.1%
This company
38.2%
Market median
+112% vs market
20202024
Return on equity
29.8%
This company
18.4%
Market median
+62% vs market
20202024
Net profit margin
25.7%
This company
8.1%
Market median
+217% vs market
20202024
Asset turnover
0.94×
This company
1.12×
Market median
+16% vs market
20202024
Debt / equity
0.23×
This company
0.62×
Market median
+63% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
PM Chief Executive Officer | Chief Executive Officer | 2022 |
NR Authorized Recipient of Service | Authorized Recipient of Service | 2022 |
SK Chief Auditor | Chief Auditor | 2026 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2022 | |
| Deputy Board Member | 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
INNOSURGE ORTHO APS
Innosurge Trauma AB (this company)Board members of Innosurge Trauma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Peter Möller Lassen | Chief Executive Officer | 0 companies |
| Nils Rune Wallner | Authorized Recipient of Service | 0 companies |
| Sara Karolina Lilja | Chief Auditor | 0 companies |
| Heinz Kvottrup Lorentzen | Chairman | 0 companies |
| Michael Maigaard Nielsen | Deputy Board Member | 0 companies |